Yueyang Liu1†
Rong Fu1†
Qi Tang1
Yaoxia Zhang1Ruiping Cai2Limin Liu3Hui Jia4
Junjia Gao3*
Ming-Sheng Zhou1*- 1Shenyang Key Laboratory of Vascular Biology, Science and Experimental Research Center of Shenyang Medical College, Shenyang, China
- 2Department of Physiology, Shenyang Medical College, Shenyang, China
- 3Department of Cardiology, 2nd Affiliated Hospital Shenyang Medical College, Shenyang, China
- 4School of Traditional Chinese Medicine, Shenyang Medical College, Shenyang, China
A Correction on
Renoprotective effects of GHRH agonist MR409 is associated with reduced oxidative stress and ferroptosis in diabetic mice
by Liu Y, Fu R, Tang Q, Zhang Y, Cai R, Liu L, Jia H, Gao J and Zhou M-S (2025). Front. Pharmacol. 16:1617185. doi: 10.3389/fphar.2025.1617185
There was a mistake in Figure 3G as published. The images for the MR409-treated group and the control group were inadvertently duplicated due to a file handling mistake during figure preparation. This was an unintentional error and does not reflect the actual experimental results, which were correctly recorded and remain valid. The corrected Figure 3 appears below.
Figure 3. MR409 attenuates the renal fibrosis in db/db and STZ-induced diabetic mice. Representative images of renal sections from db/db mice by Masson staining (A) and Sirus red staining (C), and correspondence semiquantitative analysis of positive staining area (B,D). Representative images of renal sections from STZ mice by Masson staining and Sirus red staining (E,G), and correspondence semiquantitative analysis of positive staining area (F,H). Protein expressions of TGFβ1 and Fibronectin in the kidney of db/db mice (I,J). Data are expression as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 vs. control (Ctr) group; ###P < 0.001, ##P < 0.01, #P < 0.05 vs. db/db group or STZ group. n = 6. Scale bar = 75 μm in panels (A,C,G), Scale bar = 100 μm in panels (E).
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: growth hormone-release hormone analogue, diabetic nephropathy, oxidative stress, ferroptosis, Klotho
Citation: Liu Y, Fu R, Tang Q, Zhang Y, Cai R, Liu L, Jia H, Gao J and Zhou M-S (2025) Correction: Renoprotective effects of GHRH agonist MR409 is associated with reduced oxidative stress and ferroptosis in diabetic mice. Front. Pharmacol. 16:1737333. doi: 10.3389/fphar.2025.1737333
Received: 01 November 2025; Accepted: 04 November 2025;
Published: 12 November 2025.
Edited and reviewed by:
Edgar Jaimes, Memorial Sloan Kettering Cancer Center, United StatesCopyright © 2025 Liu, Fu, Tang, Zhang, Cai, Liu, Jia, Gao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ming-Sheng Zhou, emhvdW1zMTk2M0AxNjMuY29t; Junjia Gao, NDgwMjY0ODZAcXEuY29t
†These authors have contributed equally to this work